Want to see SEER full AI Analyst Report?
SEER Stock Chart & Stats
$2.01
-$0.08(-3.90%)
At close: 4:00 PM EDT
$2.01
-$0.08(-3.90%)
Day’s Range― - ―
52-Week Range$1.55 - $2.41
Previous CloseN/A
Volume521.92K
Average Volume (3M)266.85K
Market Cap
$119.05M
Enterprise Value-$38.89M
Total Cash (Recent Filing)$152.85M
Total Debt (Recent Filing)$22.39M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Nov 10, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding55,372,017
10 Day Avg. Volume402,305
30 Day Avg. Volume266,846
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)0.41
Price to Sales (P/S)6.52
P/FCF Ratio-2.27
Enterprise Value/Market Cap-0.33
Enterprise Value/Revenue-2.81
Enterprise Value/Gross Profit-6.06
Enterprise Value/Ebitda0.62
Forecast
1Y Price Target
$4.00Price Target Upside99.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.1
Revenue Forecast (FY)$16.12M
Bulls Say, Bears Say
Bulls Say
Protected Proteomics TechnologyA substantial patent portfolio and favorable validity decisions strengthen protection around Seer’s nanoparticle enrichment and automated proteomics innovations. This can support differentiation, preserve commercialization opportunities, and improve the durability of the platform as adoption develops.
Conservative LeverageVery low leverage reduces the balance-sheet burden while Seer funds commercialization and research activities. Limited debt exposure provides greater flexibility than a heavily indebted structure, although ongoing losses still pressure equity and require careful capital allocation.
Improved Gross MarginGross-margin improvement indicates that Seer’s revenue mix and operating economics have progressed from earlier periods. If sustained as instrument utilization and consumable pull-through expand, better margins could provide operating leverage and help narrow losses over time.
Bears Say
Persistent Losses And Cash BurnSeer remains far from self-funding, with substantial operating and free-cash-flow deficits relative to its small revenue base. Persistent burn can reduce financial flexibility and may require external capital over time if commercial growth does not close the gap.
Weak Revenue MomentumRevenue contraction shows that adoption and purchasing activity have not yet produced consistent top-line expansion. A small and declining base makes fixed costs harder to absorb, while continued weakness could delay the path to scale, profitability, and durable cash generation.
Leadership And Governance UncertaintyThe departure of the president and CFO, combined with consolidation of leadership responsibilities, creates execution and oversight uncertainty during a period of losses and commercialization pressure. A transition may also affect financial controls, strategic continuity, and investor confidence.
Seer News
SEER FAQ
What was Seer’s price range in the past 12 months?
Seer lowest stock price was $1.55 and its highest was $2.41 in the past 12 months.
What is Seer’s market cap?
Seer’s market cap is $119.05M.
When is Seer’s upcoming earnings report date?
Seer’s upcoming earnings report date is Nov 10, 2026 which is in 28 days.
How were Seer’s earnings last quarter?
Seer released its earnings results on Aug 11, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.27 by -$0.04.
Is Seer overvalued?
According to Wall Street analysts Seer’s price is currently Undervalued.
Does Seer pay dividends?
Seer does not currently pay dividends.
What is Seer’s EPS estimate?
Seer’s EPS estimate is -0.26.
How many shares outstanding does Seer have?
Seer has 55,372,017 shares outstanding.
What happened to Seer’s price movement after its last earnings report?
Seer reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.27. Following the earnings report the stock price went down -0.926%.
Which hedge fund is a major shareholder of Seer?
Currently, no hedge funds are holding shares in SEER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Seer Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (99.00% Upside)
$4.00 (99.00% Upside)
Hedge Fund Trend
Decreased
By 15.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.71%
12-Months-Change
Fundamentals
Return on Equity
-27.23%
Trailing 12-Months
Asset Growth
-20.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Seer
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
SEER Company Deck
SEER Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented strong scientific, IP and strategic positives — including substantial publication momentum, independent study validation, a robust patent position, healthy cash reserves and sequential revenue improvement — but these were tempered by meaningful near-term commercial and financial challenges: year-over-year revenue decline (~24%), ongoing net losses, negative free cash flow, funding headwinds in the academic market and only modest full-year guidance (~3% growth at midpoint). The message is one of long-term conviction in the technology coupled with a cautious near-term commercial outlook.View all SEER earnings summariesSEER Stock 12 Month Forecast
Average Price Target
$4.00
▲(99.00% Upside)
Technical Analysis
Inhibikase Therapeutics
―
Surrozen
―
Instil Bio
―
TScan Therapeutics
―
Cognition Therapeutics
―
Ownership Overview
13.75% Insiders
6.18% Mutual Funds
19.53% Other Institutional Investors
56.94% Public Companies and
Individual Investors